Key result
Idarucizumab successfully and rapidly reversed the anticoagulant effects of dabigatran in three patients requiring emergency surgery or experiencing life-threatening bleeding.
Why the study?
Episodes of life-threatening bleeding associated with novel oral anticoagulants occur in clinical practice and require strategies to reverse their anticoagulant effects.
Does idarucizumab successfully reverse the anticoagulation effects of dabigatran in patients requiring urgent reversal?
Case Report (n=3)
No
Does idarucizumab successfully reverse the anticoagulation effects of dabigatran in patients requiring urgent reversal?
Idarucizumab is effective for the urgent reversal of dabigatran in real-world clinical practice.
Answers are grounded in this paper and cite their sources.
May support urgent dabigatran reversal in select cases; hypothesis-generating and leaves open need for prospective trials.
The benefits of non-Vitamin K oral antagonists in prevention or treatment of thrombosis have been studied in many randomized control trials. However, episodes of life-threatening bleeding caused by using novel oral anticoagulants have occurred in clinical practice and necessitate the development of aims for reversal of the anticoagulant effects. We report here three cases in which the use of idarucizumab, a humanized monoclonal antibody fragment, has successfully reversed the anticoagulation effects of dabigatran and produced favorable outcomes.
No takes yet. Share an insight, caveat, or question.
Hoang et al. (2020) conducted a case report in Dabigatran-induced anticoagulation requiring urgent reversal (n=3). Idarucizumab was evaluated on Reversal of anticoagulation and clinical outcome. Idarucizumab successfully and rapidly reversed the anticoagulant effects of dabigatran in three patients requiring emergency surgery or experiencing life-threatening bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: